Myeloproliferative neoplasms: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• ABL1 0
• JAK 25
• TP53 1
• PDGFR 0
• STAT3 0
• PI3K 0
• ERK 1
• FGFR 1
• FLT3 3
• mTOR 0
• AKT 0
• BCL-2 2
• IDH 3
• JNK 0
• HIF-1 0
• CSF1R 3
• HSP90 0
• MAPK 0
• MEK 2
• AMPK 0
• CD123 0
• CD19 0
• CD38 0
• IL-6 0
• KMT2A 0
• MDM2 0
• MYC 0
• NRF2 0
• PPAR 0
• RAS 0
• RUNX1 0
• ATM 0
• CD33 1
• CD40 0
• CDK4/6 1
• CXCR4 0
• EZH2 0
• G6PD 0
• HDAC 0
• KRAS 0
• NF1 0
• NLRP3 0
• NOTCH1 0
• NPM1 0
• NTRK 0
• PD-1 0
• PD-L1 0
• SGLT2 0
• SIRT1 0
• YAP 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 58+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

  NCT03627403· University of Utah· Updated 26 Oct 2026

  “PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.”Registry text, quoted unchanged. Source

• Withdrawn

  Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

  NCT06290765· PharmaEssentia· Updated 31 Jul 2026

  “In alignment with company strategic direction.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

  NCT06303193· National Cancer Institute (NCI)· Source

• Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

  NCT07750574· Chengdu Zenitar Biomedical Technology Co., Ltd· Source

• A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

  NCT06773195· Memorial Sloan Kettering Cancer Center· Source

• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

  NCT04717414· Celgene· Source

• Hematological Disorders in EHPVO Patients

  NCT07108023· Rahab Nady· Source

• Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

  NCT06605586· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 2
• Gene Expression Profiling 14
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 4
• Proteomics 7
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 19
• Immunohistochemistry 2
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 22
• Magnetic Resonance Imaging 14
• Machine Learning 7
• Deep Learning 3
• Cohort Studies 16
• Genome-Wide Association Study 1

• Lipid-lowering drugs and essential hemorrhagic thrombocythemia's risk: A drug-target Mendelian randomization study.

  Medicine (Baltimore), May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.